Marc Voigt - Executive Director & CEO - Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for ...19 hours ago — Immutep's CEO, stated, "Our late-stage and registrational trial programs continue to progress well, and we are pleased to see positive clinical ...4 days ago — A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Pointerra (ASX:3DP) and Zeus Resources (ASX:ZEU).People also ask
Media, page-470
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
-0.010(3.17%) |
Mkt cap ! $443.6M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.8¢ | 30.5¢ | $608.1K | 1.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 44 | 283963 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 187920 | 22 |
View Market Depth
| Last trade - 14.28pm 16/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |